Appaloosa, led by billionaire David Tepper, has been pressing
Allergan since last year to separate the two roles.
Allergan said last month it would split the roles, but only at
its next leadership change. Appaloosa had termed Allergan's
decision as "meaningless series of gestures" and called for a
more immediate change.
Recommendations from the two proxy firms gives firepower to CEO
Brent Saunders ahead of Allergan's May 1 shareholder meeting
where investors will vote either for or against Appaloosa's
proposal.
"Their recommendations affirm our position that our plan to
adopt separate Chair and CEO positions with the next leadership
transition is the best approach for Allergan shareholders,"
Allergan's board said in a statement.
Both ISS and Glass Lewis have asked shareholders to vote in
favor of all of Allergan's proposals.
(Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|